

Notice Regarding Refunds to 340B Covered Entities

Alcon Laboratories, Inc., a subsidiary of Alcon Vision, LLC (“Alcon”) has recalculated 340B Ceiling Prices for the products and corresponding national drug codes (“NDCs”) referenced below for the Public Health Services (“PHS”) sales period of July 1, 2019 through September 30, 2022. The recalculated Ceiling Prices are the result of restated pricing data that were submitted to the Centers for Medicare & Medicaid Services. As a result of the recalculated 340B Ceiling Prices, Alcon has determined that a refund may be owed to 340B Covered Entities that purchased the below products during the PHS sales period of July 1, 2019 through September 30, 2022 (3Q2019 – 3Q2022).

The table below identifies the products and NDCs that are subject to a refund for July 1, 2019 through September 30, 2022.

NDC 11	Product Description	PHS Sales Period(s)
00065-0303-55	ISOPTO ATROPINE 1%	4Q2019, 1Q2020, 2Q2020, 2Q2021, 3Q2021, 4Q2021, 1Q2022, 2Q2022
00065-0359-02	CYCLOMYDRIL 2ml	2Q2020, 3Q2020, 4Q2020, 2Q2022, 3Q2022
00065-0359-05	CYCLOMYDRIL 5ml	3Q2020, 4Q2020, 2Q2022, 3Q2022
00065-0395-15	CYCLOGYL 0.5%	3Q2019 - 2Q2022, 3Q2022
00065-0396-02	CYCLOGYL 1% 2ml	2Q2020, 3Q2020, 4Q2020
00065-0396-05	CYCLOGYL 1% 5ml	2Q2020, 3Q2020, 4Q2020, 3Q2022
00065-0397-02	CYCLOGYL 2% 2ml	3Q2020, 3Q2022
00065-0397-05	CYCLOGYL 2% 5ml	3Q2020, 1Q2021, 3Q2022
00065-0426-36	TEARS NATURALE FORTE 15ml	4Q2020 – 3Q2022

00065-0426-37	TEARS NATURALE FORTE 30ml	4Q2020 – 3Q2022
00065-0741-14	TETRACAINE HYDROCHLORIDE SOLUTION, 0.5%	3Q2019 - 2Q2022
00065-0530-01	EYE STREAM 30ml	4Q2020
00065-0530-04	EYE STREAM 118ml	4Q2020
00065-0795-15	BSS	1Q2022
00065-0795-50	BSS 500ML	1Q2022, 2Q2022
00065-0800-50	BSS PLUS 500ML	1Q2022, 3Q2022
00065-0800-94	BSS PLUS BAG 500ML	1Q2022, 3Q2022
00065-1795-04	BSS 500ML BAG	1Q2022, 2Q2022
00065-1795-40	BSS 500ML BAG	1Q2022, 2Q2022
00998-0355-15	MYDRIACYL 1%	3Q2019, 4Q2019, 1Q2020, 1Q2021, 2Q2021, 3Q2021, 4Q2021, 1Q2022, 2Q2022
00998-0016-15	ALCAINE	4Q2019, 1Q2020, 1Q2021, 2Q2021, 3Q2021, 4Q2021, 1Q2022, 2Q2022
00998-0408-15	ISOPTO TEARS	3Q2019, 3Q2020, 4Q2020

Based on the recalculation for the products noted above, Alcon will be working through an external 3rd party to issue refunds to each affected Covered Entity that is entitled to a refund. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to the respective Covered Entities whose wholesaler account(s) cannot be identified.

If a Covered Entity believes it is due a refund and is not contacted by the external 3rd party by April 30, 2023, the Covered Entity may then reach out to Alcon at **PHS.340B@alcon.com**.



Alcon has asked the Health Resources and Services Administration (HRSA) to post this Notice on HRSA's public website. Please direct any questions and/or requests for additional information to Alcon at the following email address: **PHS.340B@alcon.com**.